Hypertension is more common in individuals with diabetes mellitus than the general population, with estimates of the prevalence of hypertension in diabetic populations ranging from 40% to 80%. [5] [6] [7] [8] [9] [10] [11] Although previous studies have demonstrated that diabetes mellitus is associated with increased CV events and death, 5-9,11 with population-attributable risks varying from 6% to 12%, 9 it is not clear whether this risk is because of diabetes mellitus per se or because of concomitant hypertension. Certainly, trials of glucose lowering in individuals with diabetes mellitus have reported disappointingly small benefits on myocardial infarction (MI), stroke, or death. Thus, we designed this study to determine how much of the CV risk in individuals with diabetes mellitus is attributable to hypertension.
H ypertension and diabetes mellitus are increasing in prevalence, commonly coexist, and patients with both conditions are particularly vulnerable to cardiovascular (CV) disease and death. [1] [2] [3] [4] Hypertension is more common in individuals with diabetes mellitus than the general population, with estimates of the prevalence of hypertension in diabetic populations ranging from 40% to 80%. [5] [6] [7] [8] [9] [10] [11] Although previous studies have demonstrated that diabetes mellitus is associated with increased CV events and death, [5] [6] [7] [8] [9] 11 with population-attributable risks varying from 6% to 12%, 9 it is not clear whether this risk is because of diabetes mellitus per se or because of concomitant hypertension. Certainly, trials of glucose lowering in individuals with diabetes mellitus have reported disappointingly small benefits on myocardial infarction (MI), stroke, or death. Thus, we designed this study to determine how much of the CV risk in individuals with diabetes mellitus is attributable to hypertension.
Methods

Study Population
We derived the cohort for this study from both the original and offspring subjects of the Framingham Heart Study. The design and inclusion criteria of the Framingham Heart Study have been described elsewhere. 12 Although the Framingham study is a prospective cohort, our secondary analysis of the data represents a retrospective cohort study. Of the 10 333 men and women in the Framingham original (nϭ5209) and offspring (nϭ5124) cohorts, we selected those Ͼ35 years of age who had not had a CV event (defined as MI, stroke, or heart failure) before cohort entry ( Figure) : our analytic cohort thus consisted of 1145 individuals with diabetes mellitus and 5596 individuals without diabetes mellitus.
Similar to previous publications combining data from both the original and offspring Framingham cohorts, 9,13,14 we selected subjects for our cohort from 11 cycles of the original cohort examinations, taken 4 years apart and occurring from 1968 to 1996, and from all 7 cycles of the offspring examinations, taken roughly 4 years apart and occurring from 1971 to 2001. Although individuals in the Framingham cohort are repeatedly observed and contribute to more than 1 cycle, we focused our analysis on the first 4-year risk period for each individual after entry into our analytic cohort. 15 
Study Outcomes
We examined outcomes in the first 4 years of follow-up within Framingham after diagnosis of diabetes mellitus for the diabetic cohort and after Framingham entry for all of the subjects who did not develop diabetes mellitus. Our primary outcomes were all-cause mortality and CV disease (CVD)-related mortality. Information on cause of death was obtained from death certificates, medical charts, and/or family members. CVD-related death was identified as the cause of death if MI, heart failure, or stroke were responsible. Our secondary outcomes included nonfatal CVD events such as MI, heart failure, and stroke. All of the deaths and CVD events were adjudicated by a panel of 3 physicians using previously described criteria. 12 
Diabetes Mellitus and Hypertension Status Assessment
Subjects were considered to have diabetes mellitus if they had a random plasma glucose level Ն200 mg/dL (11.1 mmol/L), fasting plasma glucose Ն126 mg/dL (7.0 mmol/L), or were taking insulin or an oral hypoglycemic agent. The glycohemoglobin was not collected in any of the Framingham cycles, random glucose was collected at all of the Framingham visits except cycles 5 and 7 for the original cohort, and fasting glucose was routinely collected after cycle 3 for the offspring cohort.
At each Framingham visit, seated systolic and diastolic blood pressures (BPs) were measured twice by the examining physician using a mercury sphygmomanometer. Hypertension at the time of entry into our study cohort (ie, time of diabetes mellitus diagnosis for those with diabetes mellitus and the time of baseline Framingham assessment for those without diabetes mellitus) was defined as a systolic BP of Ն130 mm Hg or diastolic BP of Ն80 mm Hg among patients with diabetes mellitus, a systolic BP of 140 mm Hg or diastolic BP of 90 mm Hg or more among participants without diabetes mellitus, or current use of antihypertensive therapy in either group. Although our primary analysis defined subjects on the basis of their hypertension status at the time of study cohort entry, in a sensitivity analysis of our diabetic subjects we excluded subjects initially defined as "normotensive" if they developed hypertension during follow-up. We conducted other sensitivity analyses with different definitions for hypertension (Ն140/90 mm Hg in both those with and without diabetes mellitus) and examined the association between various elements of BP and outcomes imputing BP as a continuous variable into multiple linear regression models.
Covariate Assessment
At each Framingham visit, subjects underwent a physical examination and laboratory assessment of CV risk factors. Height and weight were measured, and obesity was defined as body mass index of Ն30. Current smoking was defined as Ն1 cigarette per day on average in the year before the examination. The medication history for cholesterol-lowering and antihypertensive agents was defined based on patient self-report and medical charts. Laboratory tests, including total cholesterol, high-density lipoprotein, and random/fasting glucose levels were measured as described previously. 16, 17 We did not have access to data on albuminuria, renal function, or left ventricular hypertrophy.
Statistical Analysis
Age-and sex-standardized all-cause mortality, CVD mortality, and the incidence rates (per 1000 person-years) for CVD events and their 95% CIs were calculated stratified for the presence/absence of hypertension at baseline in subjects with diabetes mellitus. The hazard ratio (HR) and 95% CI for hypertension among nondiabetic participants were also estimated in proportional hazards regression models using the initial 4 years of follow-up. 15 Three models were fitted adjusting for sequentially more covariates including age, sex, body mass index, current smoking, obesity (body mass index Ն30), hypercholesterolemia (total cholesterol Ն5.2 mmol/L or taking medication for cholesterol lowering), and low high-density lipoprotein (Ͻ1.03 mmol/L for men or Ͻ1.28 mmol/L for women).
The population-attributable risk of hypertension as a risk factor for mortality and CVD events was calculated among Framingham participants with and without diabetes mellitus using the following formula: Pϫ(HRϪ1)/(Pϫ(HRϪ1)ϩ1). P is prevalence of hypertension among the population of interest, calculated using the personyears of observation with hypertension divided by the total personyears observation, and HR is for each event associated with hypertension in each population. Cumulative incidence rates for all-cause mortality, CVD mortality, and CVD events as a function of hypertension status at baseline were estimated in proportional hazard regression models after adjustment for age and sex during 4 years of follow-up.
Descriptive data are presented as the percentage or meanϮSD. The baseline characteristics of subjects with diabetes mellitus and with/without hypertension were compared using 2 for categorical variables and t test for numeric variables. All of the statistical analyses were conducted with SAS software (SAS Enterprise Guide 9.1, SAS Institute Inc, Cary, NC), and the curves of cumulative incidence rates for mortality and CVD events were drawn using SPSS (version 16.0). Approval for this study was obtained from the University of Calgary Research Ethics Board.
Results
Of the 1145 eligible subjects with new-onset diabetes mellitus, 663 (58%) had hypertension at baseline if measured BP Ն130/80 mm Hg or current use of antihypertensive therapy was used as the definition; if measured BP Ն140/90 mm Hg or current use of antihypertensive therapy was used to define hypertension, 642 subjects with diabetes mellitus (56%) had hypertension at baseline. Of the 5596 eligible subjects without diabetes mellitus, 1309 (23%) had hypertension at baseline (using the definition of 140/90 mm Hg). All of the eligible subjects were followed for a maximum of 4 years (4154 person-years of follow-up in the diabetic cohort [median: 3.6 years] and 20 157 person-years of follow-up in the nondiabetic cohort [median: 3.7 years]). Diastolic and systolic BPs and body mass index were the only baseline characteristics that were significantly different between Framingham participants with incident diabetes mellitus who did versus did not have hypertension at the time that their diabetes mellitus was diagnosed (Table 1) . Subjects taking antihypertensive drugs had lower BPs than those with hypertension who were not taking drug therapy at baseline, 145/80 versus 149/85 mm Hg (PϽ0.001).
Age-and sex-standardized rates of all-cause mortality and CVD-related mortality among Framingham participants with diabetes mellitus were 28.7 and 20.1 per 1000 person-years, respectively. Those with hypertension at the time of diabetes mellitus diagnosis were significantly more likely to experience these outcomes than those without hypertension at the time of diabetes mellitus diagnosis (Table 2) . MI, stroke, heart failure, and the composite of any CVD event were also more common among subjects with diabetes mellitus who had hypertension compared with those without hypertension (all P values Ͻ0.01; Table 3 ). Event rates were relatively constant over time (please see the online Data Supplement at http://hyper.ahajournals.org for Figure S1 ).
On multivariate analysis, hypertension was significantly and strongly associated with increased risks for all-cause mortality and CVD-related events in both those individuals with and without diabetes mellitus (Table 4) . After adjustment for other baseline characteristics, including age, sex, smoking, obesity, and cholesterol levels, hypertension at baseline was associated with a 72% increase in the risk of all-cause death and a 57% increase in the risk of any CV event in individuals with diabetes mellitus; in those individuals without diabetes mellitus, hypertension was associated with an 81% increase in the risk of all-cause mortality and a 98% increase in the risk of any CVD event (Table 4) . Of note, the population-attributable risk from hypertension for the various outcomes ranged from 27% to 44% in individuals without diabetes mellitus and from 24% to 34% in individuals with diabetes mellitus (Table 4) . Results were very similar in a sensitivity analysis in which we defined hypertension in the diabetes mellitus cohort as measured BP Ն140/90 mm Hg or current use of antihypertensive therapy (please see Table S1 in the online Data Supplement). Baseline systolic BP, diastolic BP, pulse pressure, and mean arterial pressure (examined as continuous variables in 4 separate multivariate models) were all independently associated with increased risk of CVD death and/or CVD events in our diabetes mellitus cohort (Table S2A and S2B) .
Although a multivariate model confirmed that both hypertension and diabetes mellitus were independent risk factors with similar HRs for all-cause mortality and CVD events (Table S3) , diabetes mellitus was associated with much smaller population-attributable risks (eg, 8% for all-cause mortality and 12% for any CVD event) because of the much lower prevalence of diabetes mellitus than hypertension in these Framingham participants. Indeed, adjustment for hypertension at baseline in the multivariate models reduced the population-attributable risk from diabetes mellitus to 7% for all-cause death and 9% for any CVD event. CVD indicates cardiovascular disease; MI, myocardial infarction; HF, heart failure. Rates were adjusted for sex and age.
Of note, our estimates of the relative risks and populationattributable risks for hypertension are likely underestimates, because 23% of the individuals with diabetes mellitus who were normotensive at baseline developed hypertension during follow-up. After excluding these 110 normotensive individuals who developed hypertension during follow-up, our sensitivity analyses confirmed this in that the populationattributable risk for hypertension increased to 44% for allcause death and 41% for any CVD event (Table S4 ).
Discussion
Our key finding is that the presence of hypertension is the strongest driver of CV outcomes in individuals with diabetes mellitus. More than half of those with diabetes mellitus within the Framingham cohort had hypertension, and the population-attributable risk from hypertension exceeds 25% for any CVD event and 30% for mortality (increasing to 41% and 44% if individuals initially classified as normotensive who developed hypertension during followup were excluded from the analyses). These results suggest that the most important intervention for preventing CV events and death in individuals with diabetes mellitus is control of BP.
Our study is consistent with other studies that have demonstrated an Ϸ2-fold increased risk for CV events and deaths in diabetic individuals with hypertension compared with those with normal BPs. 4, 18 However, we have extended this evidence base by exploring the population-attributable risk associated with hypertension versus diabetes mellitus in a well-categorized cohort of individuals who have all been routinely screened for diabetes mellitus with complete follow-up and rigorous end point ascertainment and by demonstrating that, although diabetes mellitus is also associ- HR indicates hazard ratio; PAR, population-attributable risk. *PARϭ͓100*Prevalence*(HRϪ1)/(Prevalence*(HRϪ1)ϩ1͔. †Model 1 was adjusted for sex and age. ‡Model 2 was adjusted for sex, age, current smoker at baseline (yes or no), obesity (body mass index Ն30) at baseline, and hypercholesterolemia at baseline (Ͼ5.2 mmol/L total cholesterol). §Model 3 was adjusted for sex, age, current smoker at baseline (yes or no), obesity (body mass index Ն30) at baseline, hypercholesterolemia at baseline (Ն5.2 mmol/L total cholesterol), and low high-density lipoprotein at baseline (Ͻ1.03 mmol/L for men and Ͻ1.28 mmol/L for women).
ated with excess risk for CV outcomes, much of this risk is because of concomitant hypertension.
Our data are consistent with other epidemiological data demonstrating that lower BPs are associated with lower CV event rate, 11 and are also consistent with clinical trial data demonstrating that lowering BP in individuals with diabetes mellitus confers substantial clinical benefits. 6, 19, 20 Although the recent Action to Control Cardiovascular Risk in Diabetes Trial raises the possibility that lowering systolic BP below 120 mm Hg in individuals with diabetes mellitus may not confer any additional benefits over systolic pressures of 134 mm Hg, 21 it is worth noting that the baseline BPs in those with diabetes mellitus and hypertension in Framingham were substantially higher at 147/84 mm Hg.
However, there are some limitations to our study. First, we were unable to distinguish duration of hypertension, and, thus, those we identified as having hypertension at the time of incident diabetes diagnosis included a mixture of incident hypertensives and individuals with potentially long-standing hypertension but newly recognized diabetes mellitus. However, this would not invalidate our results, because the inclusion of incident hypertensives would bias our results toward the null. Similarly, we did not have data on follow-up BPs (although an analysis of serial changes in BP within Framingham reported relatively modest changes in systolic BP over time) 22 and, thus, could not examine whether those with BPs that were subsequently controlled or regressed to the mean exhibited lower event rates than those with persistently elevated BPs (although clinical trial data would certainly suggest that this should be the case). Because some of those we defined as "hypertensive" likely had BPs in the normotensive range during follow-up (because of withinperson variability in measurement and regression dilution bias), our estimates of event rates in the hypertensive subgroup were likely an underestimate, again biasing our results toward the null. In the same vein, inclusion of individuals who had normal BPs at baseline but went on to develop hypertension during follow-up in our normotensive comparator group would also have biased our results toward the null, a hypothesis confirmed by our sensitivity analysis. It is noteworthy that all of the limitations of our data set and analysis discussed thus far would have underestimated the impact of hypertension on CVD outcomes in individuals with diabetes mellitus. However, we acknowledge that we did not have any data on albuminuria, renal function, or left ventricular hypertrophy in these subjects and, thus, could not adjust for these CV risk factors in our multivariate models. In addition, although we provided data on the association among systolic BP, diastolic BP, pulse pressure, and mean arterial pressure and outcomes in Tables S2A and S2B , we acknowledge that these analyses were underpowered to definitively answer the question as to which BP measurement most strongly correlates with individual CV outcomes in individuals with diabetes mellitus.
Perspectives
Although diabetes mellitus is associated with increased risks for death and CV events in the Framingham cohort, we have established that much of this excess risk is attributable to coexistent hypertension in diabetic individuals. Increased attention to the role of BP control in preventing CV events in individuals with diabetes mellitus is essential, particularly in light of evidence that hypertension is the most poorly controlled of the cardiac risk factors in patients with diabetes mellitus, 23 ,24 yet may be the most cost-effective of the various therapeutic options. 25 
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